Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Generic name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
TBD Entrectinib Withdrawn Jul 29, 2019
TBD Trastuzumab Cancelled
TBC tralokinumab atopic dermatitis Active Apr 27, 2021
Entuzity KwikPen human insulin Diabetes mellitus Active Jan 27, 2021
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn Dec 21, 2017
Increlex mecasermin Severe primary insulin-like growth factor-1 deficiency Active Jun 14, 2021
Venclexta Venetoclax Withdrawn Jul 8, 2016
Xeljanz tofacitinib Cancelled
Tukysa tucatinib Advanced or Metastatic Breast Cancer Active Mar 26, 2021
Trintellix Vortioxetine Depression, major depressive disorder Withdrawn Oct 31, 2014